With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.34946-82-2,Copper(II) trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.
Copper(II) triflate (50.0 mg, 0.14 mmol) was dissolved in methanol (3 ml) and the ligand (42.8 mg, 0.07 mmol) added. The reaction mixture was stirred at r. t. for 16 h. Then the mixture was evaporated to dryness and the resulting green solid recrystallised from dichloromethane and pentane. 5: 23.6 mg, 34.0%. C42H37N5O8S2F6Cu¡¤2CH2Cl2: Anal. Calc. C, 43.16; H, 3.30; N, 5.59. Found: C, 42.72; H, 3.71; N, 5.87%. HR-MS: C40H36N5O263Cu Calc. 681.2239. Found: 681.2202 (100.0), C40H36N5O265Cu Calc. 683.2147. Found 683.2105 (65.1). IR: nunu [cm-1]=3066, 2962, 2870, 1657, 1598, 1535, 1484, 1454, 1265, 1172, 1109, 1032, 953, 756, 639. Magnetic susceptibility in CD2Cl2 (295 K): mueff=1.78muB., 34946-82-2
As the paragraph descriping shows that 34946-82-2 is playing an increasingly important role.
Reference£º
Article; Sauer, Desiree C.; Wadepohl, Hubert; Polyhedron; vol. 81; (2014); p. 180 – 187;,
Copper catalysis in organic synthesis – NCBI
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”